{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T13:03:37Z","timestamp":1793192617336,"version":"4.5.0"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2018,6,27]],"date-time":"2018-06-27T00:00:00Z","timestamp":1530057600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1007\/s40265-018-0937-z","type":"journal-article","created":{"date-parts":[[2018,6,27]],"date-time":"2018-06-27T02:16:21Z","timestamp":1530065781000},"page":"1037-1048","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":134,"title":["Empagliflozin: A Review in Type 2 Diabetes"],"prefix":"10.1007","volume":"78","author":[{"given":"James E.","family":"Frampton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,27]]},"reference":[{"key":"937_CR1","doi-asserted-by":"publisher","first-page":"653789","DOI":"10.1155\/2013\/653789","volume":"2013","author":"AS Matheus","year":"2013","unstructured":"Matheus AS, Tannus LR, Cobas RA, et al. Impact of diabetes on cardiovascular disease: an update. Int J Hypertens. 2013;2013:653789.","journal-title":"Int J Hypertens."},{"issue":"1","key":"937_CR2","doi-asserted-by":"publisher","first-page":"140","DOI":"10.2337\/dc14-2441","volume":"38","author":"SE Inzucchi","year":"2015","unstructured":"Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38(1):140\u20139.","journal-title":"Diabetes Care"},{"key":"937_CR3","doi-asserted-by":"publisher","first-page":"169","DOI":"10.2147\/DMSO.S61438","volume":"7","author":"D Lorber","year":"2014","unstructured":"Lorber D. Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus. Diabetes Metab Syndr Obes. 2014;7:169\u201383.","journal-title":"Diabetes Metab Syndr Obes."},{"issue":"Suppl 2","key":"937_CR4","doi-asserted-by":"publisher","first-page":"S154","DOI":"10.2337\/dcS15-3005","volume":"39","author":"JPH Wilding","year":"2016","unstructured":"Wilding JPH, Rajeev SP, DeFronzo RA. Positioning SGLT2 inhibitors\/incretin-based therapies in the treatment algorithm. Diabetes Care. 2016;39(Suppl 2):S154\u201364.","journal-title":"Diabetes Care"},{"key":"937_CR5","doi-asserted-by":"publisher","first-page":"717","DOI":"10.2337\/dc16-0041","volume":"39","author":"M Abdul-Ghani","year":"2016","unstructured":"Abdul-Ghani M, Del Prato S, Chilton R, et al. SGLT2 inhibitors and cardiovascular risk: lessons learned from the EMPA-REG OUTCOME study. Diabetes Care. 2016;39:717\u201325.","journal-title":"Diabetes Care"},{"key":"937_CR6","unstructured":"European Medicines Agency. Jardiance 10 and 25\u00a0mg film-coated tablets: summary of product characteristics. 2014. http:\/\/www.ema.europa.eu . Accessed 8 June 2018."},{"key":"937_CR7","unstructured":"Boehringer Ingelheim Pharmaceuticals, Inc. Jardiance\u00ae (empagliflozin) tablets, for oral use. US prescribing information. 2016. http:\/\/docs.boehringer-ingelheim.com\/Prescribing%20Information\/PIs\/Jardiance\/jardiance.pdf . Accessed 8 June 2018."},{"issue":"15","key":"937_CR8","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1007\/s40265-014-0298-1","volume":"74","author":"LJ Scott","year":"2014","unstructured":"Scott LJ. Empagliflozin: a review of its use in patients with type 2 diabetes mellitus. Drugs. 2014;74(15):1769\u201384.","journal-title":"Drugs."},{"issue":"3","key":"937_CR9","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s40262-013-0126-x","volume":"53","author":"AJ Scheen","year":"2014","unstructured":"Scheen AJ. Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor. Clin Pharmacokinet. 2014;53(3):213\u201325.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"937_CR10","first-page":"1","volume":"12","author":"MJ Levine","year":"2016","unstructured":"Levine MJ. Empagliflozin for type 2 diabetes mellitus: an overview of phase 3 clinical trials. Curr Diabetes Rev. 2016;12(4):1\u201319.","journal-title":"Curr Diabetes Rev"},{"issue":"4","key":"937_CR11","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1111\/1753-0407.12278","volume":"7","author":"G Dailey","year":"2015","unstructured":"Dailey G. Empagliflozin for the treatment of type 2 diabetes mellitus: an overview of safety and efficacy based on phase 3 trials. J Diabetes. 2015;7(4):448\u201361.","journal-title":"J Diabetes."},{"issue":"3","key":"937_CR12","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/S2213-8587(13)70084-6","volume":"1","author":"M Roden","year":"2013","unstructured":"Roden M, Weng J, Eilbracht J, et al. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2013;1(3):208\u201319.","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"6","key":"937_CR13","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.2337\/dc13-2105","volume":"37","author":"H-U H\u04d3ring","year":"2014","unstructured":"H\u04d3ring H-U, Merker L, Seewaldt-Becker E, et al. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week randomized, double-blind, placebo-controlled trial. Diabetes Care. 2014;37(6):1650\u20139.","journal-title":"Diabetes Care"},{"issue":"11","key":"937_CR14","doi-asserted-by":"publisher","first-page":"3396","DOI":"10.2337\/dc12-2673","volume":"36","author":"H-U H\u04d3ring","year":"2013","unstructured":"H\u04d3ring H-U, Merker L, Seewaldt-Becker E, et al. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care. 2013;36(11):3396\u2013404.","journal-title":"Diabetes Care"},{"issue":"2","key":"937_CR15","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/dom.12188","volume":"16","author":"CS Kovacs","year":"2014","unstructured":"Kovacs CS, Seshiah V, Swallow R, et al. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab. 2014;16(2):147\u201358.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"937_CR16","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2337\/dc16-1347","volume":"40","author":"E S\u00f8fteland","year":"2017","unstructured":"S\u00f8fteland E, Meier JJ, Vangen B, et al. Empagliflozin as add-on therapy in patients with type 2 diabetes inadequately controlled with linagliptin and metformin: a 24-week randomized, double-blind, parallel-group trial. Diabetes Care. 2017;40(2):201\u20139.","journal-title":"Diabetes Care"},{"issue":"3","key":"937_CR17","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/S2213-8587(14)70120-2","volume":"2","author":"M Ridderstrale","year":"2014","unstructured":"Ridderstrale M, Andersen RK, Zeller C, et al. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week, randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol. 2014;2(3):691\u2013700.","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"10","key":"937_CR18","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1111\/dom.12503","volume":"17","author":"J Rosenstock","year":"2015","unstructured":"Rosenstock J, Jelaska A, Zeller C, et al. Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2015;17(10):936\u201348.","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"937_CR19","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/S2213-8587(13)70208-0","volume":"2","author":"AH Barnett","year":"2014","unstructured":"Barnett AH, Mithal A, Manassie J, et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2014;2(5):369\u201384.","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"3","key":"937_CR20","doi-asserted-by":"publisher","first-page":"420","DOI":"10.2337\/dc14-1096","volume":"38","author":"I Tikkanen","year":"2015","unstructured":"Tikkanen I, Narko K, Zeller C, et al. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care. 2015;38(3):420\u20138.","journal-title":"Diabetes Care"},{"key":"937_CR21","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.2337\/dc13-3055","volume":"37","author":"J Rosenstock","year":"2014","unstructured":"Rosenstock J, Jelaska A, Frappin G, et al. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycaemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes Care. 2014;37:1815\u201323.","journal-title":"Diabetes Care"},{"key":"937_CR22","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s12933-015-0314-0","volume":"14","author":"M Roden","year":"2015","unstructured":"Roden M, Merker L, Christiansen AV, et al. Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naive patients with type 2 diabetes: a double-blind extension of a phase III randomized controlled trial. Cardiovasc Diabetol. 2015;14:154.","journal-title":"Cardiovasc Diabetol."},{"issue":"12","key":"937_CR23","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1111\/dme.12814","volume":"32","author":"L Merker","year":"2015","unstructured":"Merker L, Haring HU, Christiansen AV, et al. Empagliflozin as add-on to metformin in people with type 2 diabetes. Diabet Med. 2015;32(12):1555\u201367.","journal-title":"Diabet Med"},{"issue":"1","key":"937_CR24","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.diabres.2015.05.044","volume":"110","author":"H-U Haering","year":"2015","unstructured":"Haering H-U, Merker L, Christiansen AV, et al. Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes. Diabetes Res Clin Pract. 2015;110(1):82\u201390.","journal-title":"Diabetes Res Clin Pract"},{"key":"937_CR25","doi-asserted-by":"crossref","unstructured":"Kovacs CS, Seshiah V, Merker L, et al. Empagliflozin as add-on therapy to pioglitazone with or without metformin in patients with type 2 diabetes mellitus. Clin Ther. 2015;37(8):1773\u201388.e1.","DOI":"10.1016\/j.clinthera.2015.05.511"},{"key":"937_CR26","doi-asserted-by":"crossref","unstructured":"Ridderstrale M, Elsasser U, Zeller C, et al. Influence of baseline HbA1c, BMI, beta-cell function, and insulin sensitivity on the treatment response of empagliflozin (EMPA) in patients with type 2 diabetes (T2DM) [abstract no. 118-LB]. Diabetes. 2015;64(Suppl 1A):LB31.","DOI":"10.1055\/s-0036-1580784"},{"issue":"10","key":"937_CR27","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.endoen.2016.11.001","volume":"63","author":"I Romera","year":"2016","unstructured":"Romera I, Ampudia-Blasco FJ, Perez A, et al. Efficacy and safety of empagliflozin in combination with other oral hypoglycemic agents in patients with type 2 diabetes mellitus. Endocrinologia y Nutricion (English Edition). 2016;63(10):519\u201326.","journal-title":"Endocrinologia y Nutricion (English Edition)."},{"issue":"1","key":"937_CR28","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.kint.2017.06.017","volume":"93","author":"DZI Cherney","year":"2018","unstructured":"Cherney DZI, Cooper ME, Tikkanen I, et al. Pooled analysis of phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin. Kidney Int. 2018;93(1):231\u201344.","journal-title":"Kidney Int"},{"key":"937_CR29","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/1475-2840-13-102","volume":"13","author":"B Zinman","year":"2014","unstructured":"Zinman B, Inzucchi SE, Lachin JM, et al. Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME\u2122). Cardiovasc Diabetol. 2014;13:102.","journal-title":"Cardiovasc Diabetol."},{"issue":"22","key":"937_CR30","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117\u201328.","journal-title":"N Engl J Med"},{"key":"937_CR31","unstructured":"EMA. Assessment report. Jardiance. International non-proprietary name: empagliflozin. Procedure No. EMEA\/H\/C\/002677\/II\/0014. http:\/\/www.ema.europa.eu . Accessed 8 June 2018."},{"issue":"19","key":"937_CR32","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1093\/eurheartj\/ehv728","volume":"37","author":"D Fitchett","year":"2016","unstructured":"Fitchett D, Zinman B, Wanner C, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME trial. Eur Heart J. 2016;37(19):1526\u201334.","journal-title":"Eur Heart J"},{"issue":"4","key":"937_CR33","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1515920","volume":"375","author":"C Wanner","year":"2016","unstructured":"Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323\u201334.","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"937_CR34","first-page":"S85","volume":"60","author":"J Schnee","year":"2017","unstructured":"Schnee J, Inzucchi SE, Zinman B, et al. Consistent effect of empagliflozin on composite outcomes related to heart failure: results from EMPA-REG OUTCOME [abstract no. 182]. Diabetologia. 2017;60(Suppl 1):S85\u20136.","journal-title":"Diabetologia"},{"issue":"Suppl 1","key":"937_CR35","first-page":"S21","volume":"60","author":"D Fitchett","year":"2017","unstructured":"Fitchett D, Mathieu C, Kaspers S, et al. Empagliflozin (EMPA) reduces mortality in analyses adjusted for control of blood pressure (BP), low density lipoprotein cholesterol (LDL-C) and HbA1c over time [abstract no. 42]. Diabetologia. 2017;60(Suppl 1):S21.","journal-title":"Diabetologia"},{"key":"937_CR36","doi-asserted-by":"crossref","unstructured":"McKnight J, Fitchett D, Lee J, et al. Empagliflozin (EMPA) reduces heart failure outcomes irrespective of blood pressure (BP), low density lipoprotein cholesterol (LDL-C) and HbA1c control [abstract no. 899]. Diabetologia. 2017;60(1 Suppl 1):S416\u20137.","DOI":"10.1016\/j.cjca.2017.07.336"},{"issue":"2","key":"937_CR37","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1161\/CIRCULATIONAHA.117.028268","volume":"137","author":"C Wanner","year":"2018","unstructured":"Wanner C, Lachin JM, Inzucchi SE, et al. Empagliflozin and clinical outcomes in patients with type 2 diabetes, established cardiovascular disease and chronic kidney disease. Circulation. 2018;137(2):119\u201329.","journal-title":"Circulation"},{"issue":"2","key":"937_CR38","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1253\/circj.CJ-16-1148","volume":"81","author":"K Kaku","year":"2017","unstructured":"Kaku K, Lee J, Mattheus M, et al. Empagliflozin and cardiovascular outcomes in Asian patients with type 2 diabetes and established cardiovascular disease - results from EMPA-REG OUTCOME. Circ J. 2017;81(2):227\u201334.","journal-title":"Circ J"},{"issue":"4","key":"937_CR39","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1161\/CIRCULATIONAHA.117.032031","volume":"137","author":"S Verma","year":"2017","unstructured":"Verma S, Mazer CD, Al-Omran M, et al. Cardiovascular outcomes and safety of empagliflozin in patients with type 2 diabetes mellitus and peripheral artery disease: a subanalysis of EMPA-REG OUTCOME. Circulation. 2017;137(4):405\u20137.","journal-title":"Circulation."},{"issue":"10","key":"937_CR40","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1111\/dom.12734","volume":"18","author":"A Salsali","year":"2016","unstructured":"Salsali A, Kim G, Woerle HJ, et al. Cardiovascular safety of empagliflozin in patients with type 2 diabetes: a meta-analysis of data from randomized placebo-controlled trials. Diabetes Obes Metab. 2016;18(10):1034\u201340.","journal-title":"Diabetes Obes Metab"},{"issue":"Suppl 6","key":"937_CR41","doi-asserted-by":"publisher","first-page":"S63","DOI":"10.1016\/j.amjmed.2017.04.007","volume":"130","author":"C Wanner","year":"2017","unstructured":"Wanner C. EMPA-REG OUTCOME: the nephrologist\u2019s point of view. Am J Med. 2017;130(Suppl 6):S63\u201372.","journal-title":"Am J Med"},{"issue":"18","key":"937_CR42","first-page":"1801","volume":"375","author":"C Wanner","year":"2016","unstructured":"Wanner C, Inzucchi SE, Zinman B. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(18):1801\u20132.","journal-title":"N Engl J Med"},{"issue":"7","key":"937_CR43","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1007\/s12325-017-0573-0","volume":"34","author":"S Kohler","year":"2017","unstructured":"Kohler S, Zeller C, Iliev H, et al. Safety and tolerability of empagliflozin in patients with type 2 diabetes: pooled analysis of phase I\u2013III clinical trials. Adv Ther. 2017;34(7):1707\u201326.","journal-title":"Adv Ther."},{"issue":"Suppl 1","key":"937_CR44","first-page":"A325","volume":"66","author":"A Levin","year":"2017","unstructured":"Levin A, Nangaku M, Kadowaki T, et al. Safety and tolerability of empagliflozin in patients with t2d and advanced kidney disease: a large, pooled analysis of placebo-controlled clinical trials (abstract no. 1218-P plus poster). Diabetes. 2017;66(Suppl 1):A325.","journal-title":"Diabetes"},{"issue":"Suppl 1","key":"937_CR45","first-page":"S26","volume":"59","author":"S Lund","year":"2016","unstructured":"Lund S, Solimando F, Kohler S, et al. Effect of empagliflozin (EMPA) on diabetic ketoacidosis (DKA) in patients with type 2 diabetes (T2DM): pooled clinical trial data [abstract no. 50]. Diabetologia. 2016;59(Suppl 1):S26\u20137.","journal-title":"Diabetologia"},{"key":"937_CR46","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1093\/ehjcvp\/pvw009","volume":"2","author":"AE Leeuw de","year":"2016","unstructured":"de Leeuw AE, de Boer R. Sodium\u2013glucose cotransporter 2 inhibition: cardioprotection by treating diabetes\u2014a translational viewpoint explaining its potential salutary effects. Eur Heart J Cardiovasc Pharmacother. 2016;2:244\u201355.","journal-title":"Eur Heart J Cardiovasc Pharmacother."},{"issue":"2","key":"937_CR47","doi-asserted-by":"publisher","first-page":"356","DOI":"10.2337\/dc17-1096","volume":"41","author":"SE Inzucchi","year":"2018","unstructured":"Inzucchi SE, Zinman B, Fitchett D, et al. How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial. Diabetes Care. 2018;41(2):356\u201363.","journal-title":"Diabetes Care"},{"issue":"1","key":"937_CR48","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12933-017-0532-8","volume":"16","author":"A Tanaka","year":"2017","unstructured":"Tanaka A, Shimabukuro M, Okada Y, et al. Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial. Cardiovasc Diabetol. 2017;16(1):48.","journal-title":"Cardiovasc Diabetol."},{"issue":"1","key":"937_CR49","doi-asserted-by":"publisher","first-page":"14","DOI":"10.2337\/dci17-0057","volume":"41","author":"WT Cefalu","year":"2018","unstructured":"Cefalu WT, Kaul S, Gerstein HC, et al. Cardiovascular outcomes trials in type 2 diabetes: where do we go from here? Reflections from a Diabetes Care Editors\u2019 Expert Forum. Diabetes Care. 2018;41(1):14\u201331.","journal-title":"Diabetes Care"},{"key":"937_CR50","unstructured":"Boehringer Ingelheim. Boehringer Ingelheim and Lilly announce an academic collaboration with University of Oxford to investigate the effects of empagliflozin in people with chronic kidney disease [media release]. 18 Apr 2018. https:\/\/www.boehringer-ingelheim.com ."},{"issue":"2","key":"937_CR51","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s40265-017-0857-3","volume":"78","author":"DR Saxon","year":"2018","unstructured":"Saxon DR, Rasouli N, Eckel RH. Pharmacological prevention of cardiovascular outcomes in diabetes mellitus: established and emerging agents. Drugs. 2018;78(2):203\u201314.","journal-title":"Drugs."},{"issue":"3","key":"937_CR52","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1161\/CIRCULATIONAHA.117.029190","volume":"136","author":"M Kosiborod","year":"2017","unstructured":"Kosiborod M, Cavender MA, Fu AZ, et al. Lower risk of heart failure and death in patients initiated on SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study. Circulation. 2017;136(3):249\u201359.","journal-title":"Circulation"},{"issue":"23","key":"937_CR53","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1016\/j.jacc.2018.03.009","volume":"71","author":"M Kosiborod","year":"2018","unstructured":"Kosiborod M, Lam CSP, Kohsaka S, et al. Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL 2 study. J Am Coll Cardiol. 2018;71(23):2628\u201339.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"937_CR54","doi-asserted-by":"publisher","first-page":"e009417","DOI":"10.1136\/bmjopen-2015-009417","volume":"6","author":"DS Shyangdan","year":"2016","unstructured":"Shyangdan DS, Uthman OA, Waugh N. SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis. BMJ Open. 2016;6(2):e009417.","journal-title":"BMJ Open"},{"issue":"8","key":"937_CR55","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1111\/dom.12670","volume":"18","author":"F Zaccardi","year":"2016","unstructured":"Zaccardi F, Webb DR, Htike ZZ, et al. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. Diabetes Obes Metab. 2016;18(8):783\u201394.","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"937_CR56","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/s41574-018-0001-9","volume":"14","author":"AJ Scheen","year":"2018","unstructured":"Scheen AJ. Does lower limb amputation concern all SGLT2 inhibitors? Nat Rev Endocrinol. 2018;14(6):326\u20138.","journal-title":"Nat Rev Endocrinol."},{"issue":"1","key":"937_CR57","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.2337\/dc17-1551","volume":"41","author":"SE Inzucchi","year":"2018","unstructured":"Inzucchi SE, Iliev H, Pfarr E, et al. Empagliflozin and assessment of lower-limb amputations in the EMPA-REG OUTCOME trial. Diabetes Care. 2018;41(1):e4\u20135.","journal-title":"Diabetes Care"},{"issue":"4","key":"937_CR58","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1111\/dom.13176","volume":"20","author":"KA Toulis","year":"2018","unstructured":"Toulis KA, Bilezikian JP, Thomas GN, et al. Initiation of dapagliflozin and treatment-emergent fractures. Diabetes Obes Metab. 2018;20(4):1070\u20134.","journal-title":"Diabetes Obes Metab"},{"key":"937_CR59","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1056\/NEJMc1701990","volume":"376","author":"M Fralick","year":"2017","unstructured":"Fralick M, Schneeweiss S, Patorno E. Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor. N Engl J Med. 2017;376:2300\u20132.","journal-title":"N Engl J Med"},{"issue":"8","key":"937_CR60","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.2337\/dc16-0885","volume":"39","author":"H Tang","year":"2016","unstructured":"Tang H, Li D, Wang T, et al. Effect of sodium-glucose cotransporter 2 inhibitors on diabetic ketoacidosis among patients with type 2 diabetes: a meta-analysis of randomized controlled trials. Diabetes Care. 2016;39(8):e123\u20134.","journal-title":"Diabetes Care"},{"key":"937_CR61","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.2337\/dc15-1380","volume":"38","author":"J Rosenstock","year":"2015","unstructured":"Rosenstock J, Ferrannini E. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care. 2015;38:1638\u201342.","journal-title":"Diabetes Care"},{"key":"937_CR62","doi-asserted-by":"crossref","unstructured":"American Diabetes Association. Pharmacological approaches to glycemic treatment. Sect. 8. In: Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018;41(Suppl 1):S73\u201385.","DOI":"10.2337\/dc18-S008"},{"issue":"1","key":"937_CR63","doi-asserted-by":"publisher","first-page":"91","DOI":"10.4158\/CS-2017-0153","volume":"24","author":"AJ Garber","year":"2018","unstructured":"Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm-2018 executive summary. Endocr Pract. 2018;24(1):91\u2013120.","journal-title":"Endocr Pract."},{"issue":"Suppl 1","key":"937_CR64","first-page":"S61","volume":"37","author":"Canadian Diabetes Association Clinical Practice Guidelines Expert Committee","year":"2013","unstructured":"Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Pharmacologic management of type 2 diabetes. Can J Diabetes. 2013;37(Suppl 1):S61\u20138.","journal-title":"Can J Diabetes."},{"issue":"Suppl 2","key":"937_CR65","doi-asserted-by":"publisher","first-page":"S137","DOI":"10.2337\/dcS15-3007","volume":"39","author":"A Cahn","year":"2016","unstructured":"Cahn A, Cefalu WT. Clinical considerations for use of initial combination therapy in type 2 diabetes. Diabetes Care. 2016;39(Suppl 2):S137\u201345.","journal-title":"Diabetes Care"},{"key":"937_CR66","unstructured":"Diabetes Canada. Pharmacologic management of type 2 diabetes: November 2016 interim update. http:\/\/guidelines.diabetes.ca . Accessed 8 June 2018."},{"issue":"27","key":"937_CR67","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016;37(27):2129\u2013200.","journal-title":"Eur Heart J"},{"issue":"7","key":"937_CR68","doi-asserted-by":"publisher","first-page":"A674","DOI":"10.1016\/j.jval.2016.09.1882","volume":"19","author":"SR Mettam","year":"2016","unstructured":"Mettam SR, Bajaj H, Kansal AR, et al. Cost effectiveness of empagliflozin in patients with T2DM and high CV risk in Canada [abstract no. PDB52]. Value Health. 2016;19(7):A674.","journal-title":"Value Health."},{"issue":"7","key":"937_CR69","doi-asserted-by":"publisher","first-page":"A673","DOI":"10.1016\/j.jval.2016.09.1876","volume":"19","author":"I Daacke","year":"2016","unstructured":"Daacke I, Kandaswamy P, Tebboth A, et al. Cost-effectiveness of empagliflozin (jardiance) in the treatment of patients with type 2 diabetes mellitus (T2DM) in the UK based on EMPA-REG outcome data [abstract no. PDB46]. Value Health. 2016;19(7):A673.","journal-title":"Value Health."},{"key":"937_CR70","unstructured":"NICE. Type 2 diabetes in adults: management. 2017. http:\/\/www.nice.org . Accessed 8 June 2018."},{"issue":"7","key":"937_CR71","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1111\/dom.12073","volume":"15","author":"T Heise","year":"2013","unstructured":"Heise T, Seewaldt-Becker E, Macha S, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics following 4\u00a0weeks\u2019 treatment with empagliflozin once daily in patients with type 2 diabetes. Diabetes Obes Metab. 2013;15(7):613\u201321.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"937_CR72","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1172\/JCI72227","volume":"124","author":"E Ferrannini","year":"2014","unstructured":"Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 2014;124(2):499\u2013508.","journal-title":"J Clin Invest."},{"issue":"4","key":"937_CR73","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1210\/jc.2017-01838","volume":"103","author":"H Al Jobori","year":"2018","unstructured":"Al Jobori H, Daniele G, Adams J, et al. Empagliflozin treatment is associated with improved beta cell function in T2DM. J Clin Endocrinol Metab. 2018;103(4):1402\u20137.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"937_CR74","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1111\/bcp.12453","volume":"78","author":"MM Riggs","year":"2014","unstructured":"Riggs MM, Seman LJ, Staab A, et al. Exposure-response modelling for empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in patients with type 2 diabetes. Br J Clin Pharmacol. 2014;78(6):1407\u201318.","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"937_CR75","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1111\/dom.12572","volume":"17","author":"R Chilton","year":"2015","unstructured":"Chilton R, Tikkanen I, Cannon CP, et al. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obes Metab. 2015;17(12):1180\u201393.","journal-title":"Diabetes Obes Metab"},{"issue":"Suppl 1","key":"937_CR76","first-page":"A119","volume":"66","author":"RJ Chilton","year":"2017","unstructured":"Chilton RJ, Gullestad L, Fitchett D, et al. Effects of empagliflozin on cardiac and vascular hemodynamic markers by subgroups of age, sex, and hypertension in patients with T2DM and high CV Risk: EMPA-REG OUTCOME [abstract no. 452-P and poster]. Diabetes. 2017;66(Suppl 1):A119.","journal-title":"Diabetes"},{"issue":"2","key":"937_CR77","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1177\/1479164115616901","volume":"13","author":"IJ Neeland","year":"2016","unstructured":"Neeland IJ, McGuire DK, Chilton R, et al. Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus. Diab Vasc Dis Res. 2016;13(2):119\u201326.","journal-title":"Diab Vasc Dis Res."},{"issue":"Suppl 1","key":"937_CR78","first-page":"S348","volume":"59","author":"IJ Neeland","year":"2016","unstructured":"Neeland IJ, McGuire DK, Fernandez CS, et al. Effect of empagliflozin on anthropometry and indices of visceral and total adiposity in patients with type 2 diabetes and high cardiovascular risk: EMPA-REG OUTCOME [abstract no. 730]. Diabetologia. 2016;59(Suppl 1):S348.","journal-title":"Diabetologia"},{"issue":"9","key":"937_CR79","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1007\/s00125-016-4008-2","volume":"59","author":"D Cherney","year":"2016","unstructured":"Cherney D, Lund SS, Perkins BA, et al. The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes. Diabetologia. 2016;59(9):1860\u201370.","journal-title":"Diabetologia"},{"issue":"8","key":"937_CR80","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/S2213-8587(17)30182-1","volume":"5","author":"DZI Cherney","year":"2017","unstructured":"Cherney DZI, Zinman B, Inzucchi SE, et al. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2017;5(8):610\u201321.","journal-title":"Lancet Diabetes Endocrinol."},{"key":"937_CR81","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.1016\/j.amjmed.2017.04.006","volume":"130","author":"SV Pham","year":"2017","unstructured":"Pham SV, Chilton R. EMPA-REG OUTCOME: the cardiologist\u2019s point of view. Am J Med. 2017;130:S57\u201362.","journal-title":"Am J Med"},{"issue":"1","key":"937_CR82","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jdiacomp.2015.10.013","volume":"30","author":"RA Defronzo","year":"2016","unstructured":"Defronzo RA. The EMPA-REG study: what has it told us? A diabetologist\u2019s perspective. J Diabetes Complicat. 2016;30(1):1\u20132.","journal-title":"J Diabetes Complicat."},{"issue":"6","key":"937_CR83","doi-asserted-by":"publisher","first-page":"520","DOI":"10.3109\/00498254.2014.999141","volume":"45","author":"LZ Chen","year":"2015","unstructured":"Chen LZ, Jungnik A, Mao Y, et al. Biotransformation and mass balance of the SGLT2 inhibitor empagliflozin in healthy volunteers. Xenobiotica. 2015;45(6):520\u20139.","journal-title":"Xenobiotica"},{"issue":"1","key":"937_CR84","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s40265-014-0337-y","volume":"75","author":"AJ Scheen","year":"2015","unstructured":"Scheen AJ. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs. 2015;75(1):33\u201359.","journal-title":"Drugs."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-018-0937-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-018-0937-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-018-0937-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T10:34:39Z","timestamp":1751711679000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-018-0937-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,27]]},"references-count":84,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["937"],"URL":"https:\/\/doi.org\/10.1007\/s40265-018-0937-z","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,27]]},"assertion":[{"value":"27 June 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"James Frampton is a salaried employee of Adis\/Springer, is responsible for the article content and declares no relevant conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}